Mohammad Afshar is Managing Partner at Opus Three and the President and CEO of Ariana Pharma, a leading digital health Company he founded in 2003. At Ariana, Dr. Afshar developed and commercialized a groundbreaking data analysis technology based on formal concept analysis, which now provides the core of Opus Three’s data analytic platform.
Prior to this, Dr. Afshar was one of the founders and the Director of Drug Design and IT at RiboTargets, Cambridge, UK, leading the computer aided discovery of novel anti-cancer and anti-infective molecules.
Before joining RiboTargets, Mohammad held several positions in academic institutions including the Department of Chemistry at the University of York, UK and the Department of Artificial Intelligence of the LIRMM-CNRS in Montpellier, France. He holds a Medical Degree (DCEM), MPhil in Artificial Intelligence (DEA), a PhD in structural biochemistry and a “Habilitation Doctorate” (HDR) from the Faculty of Medicine of the University of Montpellier, France.